Table 1 Genes regulated after treatment of the indicated ovarian cancer cell lines with the specific ERβ agonists ERB-041, Liquiritigenin (LIQ.) and WAY − 2,000,070 for 48 h. Shown are genes with at least 2-fold regulation in one experimental setting (values in italics). Data were assessed by means of Affymetrix GeneChip 1.0 microarray analyses and are expressed in -fold change compared to the vehicle control
From: Effect of estrogen receptor β agonists on proliferation and gene expression of ovarian cancer cells
OAW-42 | OVCAR-3 | |||||
|---|---|---|---|---|---|---|
ERB-041 | LIQ. | WAY200070 | ERB-041 | LIQ. | WAY200070 | |
Up-regulated genes | ||||||
C6ORF99 | 2,52 | 3,81 | 1,91 | 1,35 | 1,01 | -1,17 |
TPTE2 | 1,67 | 2,05 | 2,26 | 1,05 | 1,22 | 1,08 |
CD177 | 1,55 | −1,08 | 2,14 | 1,53 | 1,62 | 1,79 |
Down-regulated genes | ||||||
LINC00314 | 1,24 | -1,26 | -1,44 | -1,86 | −2,09 | -2,71 |
EPCAM | -1,35 | −1,41 | -2,20 | −1,21 | -1,02 | -1,05 |
SNORD25 | -2,07 | −1,07 | −2,00 | −1,03 | −1,11 | -1,07 |
RNU4-2 | -1,46 | −2,09 | −1,49 | −1,16 | −1,21 | -1,03 |
RNU2-1 | -1,62 | -1,57 | −2,05 | −1,29 | −1,03 | -1,30 |
PTCH2 | -1,67 | −1,76 | −2,08 | −1,37 | −1,10 | -1,33 |
RNU5B-1 | -1,51 | -1,79 | −2,54 | −1,11 | −1,23 | -1,09 |
ND6 | -2,11 | −2,12 | −4,01 | −1,38 | −1,11 | 1,42 |
FAM48B2 | -1,29 | −1,30 | −1,73 | −2,11 | −1,72 | -1,76 |
LCN1 | -2,28 | −1,12 | −1,11 | −2.14 | −2,38 | -1,61 |
SNORA1 | -1,82 | −2,07 | −2,09 | −1,39 | −1,41 | −1,71 |